ArticleInfectious diseases and therapy2026
Clinical-Microbiological Discordance and Delayed Mortality in OXA-48/ESBL-Producing Proteus mirabilis Infections.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
introductionOXA-48/extended-spectrum β-lactamase (ESBL)-producing Proteus mirabilis may appear susceptible to carbapenems in routine testing, potentially resulting in inappropriate therapeutic decisions. We aimed to evaluate clinical outcomes and the association between antimicrobial therapy and mortality.
methodsWe conducted a single-center observational study including 1254 patients with P. mirabilis infections (2017-2024). Seventy-nine OXA-48/ESBL cases (6.3%) were matched 2:1 with non-OXA-48/ESBL controls based on age, comorbidity, infection source, and severity. OXA-48 production was detected using the NG-Test CARBA 5 immunochromatographic assay, while ESBL production was inferred phenotypically using cefotaxime, ceftazidime, and cefepime discs alone and in combination with clavulanic acid. Predictors of 30-day mortality were assessed using time-dependent Cox regression models.
resultsOXA-48/ESBL-producing infections were associated with higher 30-day mortality (absolute difference 19.7%; population attributable fraction 18.2%). Differences in mortality emerged after day 8, suggesting delayed clinical deterioration. In time-dependent models, OXA-48/ESBL status was not associated with early mortality (days 0-7) but strongly predicted late mortality [hazard ratio (HR) 14.5; 95% confidence interval (CI) 3.19-65.93; p = 0.001]. Among patients with OXA-48/ESBL infections, carbapenem-based regimens were associated with higher mortality than alternative active therapies (50% vs. 20%; p = 0.04), remaining significant after adjustment (HR 3.37; 95% CI 1.27-8.9), although residual confounding by indication cannot be excluded.
conclusionThese observational findings support cautious interpretation of carbapenem susceptibility results and highlight the value of early carbapenemase detection to guide appropriate therapy. Graphical abstract available for this article.
Indexed as
Identifiers
42836950What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.